Department of Respiratory, the First Affiliated Hospital of Shantou University Medical College, No.57 at Changping Road, Jinping District, Shantou City, 515041, Guangdong Province, People's Republic of China.
Biol Trace Elem Res. 2021 May;199(5):1771-1777. doi: 10.1007/s12011-020-02314-5. Epub 2020 Sep 18.
Serum concentrations of magnesium and manganese may be associated with increased chronic obstructive pulmonary disease exacerbation risk. However, associations with other aspects of asthma-chronic obstructive pulmonary disease overlap, pulmonary function test results and health status, have been studied less extensively. The aim of this study was to investigate the associations between serum concentrations of trace elements and T lymphocyte subsets, FeNO, and COPD-related questionnaire scores in individuals with ACO and the potential impact of these parameters on lung function. All the patients met the diagnostic criteria of ACO and were divided into two groups (group A, mild-moderate; group B, severe-very severe) by their specific characteristics. Pulmonary function testing and serum Mg and serum Mn and FeNO were measured. Four hundred sixty-five patients were screened, and 42 were included. Group A had significantly higher Mg and Fe concentrations than group B. No significant differences were seen in the serum concentration of any other trace element between the two groups. Serum Mg and Mn were correlated with FEV1% predicted (p < 0.01). Group A had a significantly higher FeNO concentration than group B (p = 0.005). The scores on CAT (p = 0.011) and mMRC (p = 0.008) in group A were lower than in group B. The low-FeNO group had a significantly lower concentration of serum Mg than the high-FeNO group (p = 0.03). Pulmonary function declined faster (p < 0.05) in the low-FeNO group than the high-FeNO group. Serum Mg concentration may indicate protective effects against lung function loss in ACO. This implies that FeNO might be a biomarker for identifying individuals with ACO who might benefit from inhaled corticosteroid therapy. Serum Mg and FeNO were associated with ACO severity. However, their role in guiding personalised treatment of individuals with ACO needs to be further investigated.
血清镁和锰浓度可能与慢性阻塞性肺疾病加重风险增加有关。然而，人们对哮喘-慢性阻塞性肺疾病重叠的其他方面（如肺功能测试结果和健康状况）的研究则较少。本研究旨在探讨血清微量元素浓度与 T 淋巴细胞亚群、FeNO 和 COPD 相关问卷评分在 ACO 患者中的相关性，以及这些参数对肺功能的潜在影响。所有患者均符合 ACO 的诊断标准，并根据其具体特征分为两组（A 组，轻度至中度；B 组，重度至极重度）。进行肺功能测试以及测量血清镁和血清锰和 FeNO。共筛选了 465 例患者，其中 42 例患者纳入研究。A 组的血清镁和铁浓度明显高于 B 组。两组间其他微量元素血清浓度无显著差异。血清镁和锰与 FEV1%预计值相关（p<0.01）。A 组的 FeNO 浓度明显高于 B 组（p=0.005）。A 组的 CAT 评分（p=0.011）和 mMRC 评分（p=0.008）均低于 B 组。低 FeNO 组的血清镁浓度明显低于高 FeNO 组（p=0.03）。低 FeNO 组的肺功能下降速度明显快于高 FeNO 组（p<0.05）。血清镁浓度可能提示对 ACO 肺功能丧失具有保护作用。这意味着 FeNO 可能是一种生物标志物，可用于识别可能受益于吸入皮质激素治疗的 ACO 患者。血清镁和 FeNO 与 ACO 严重程度相关。然而，它们在指导 ACO 个体化治疗中的作用需要进一步研究。
